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Purpose. Nonmuscle invasive bladder cancer (BCa) has a high recurrence rate requiring lifelong surveillance. Urinary biomarkers
are promising as simple alternatives to cystoscopy for the diagnosis of recurrent bladder cancer. However, no single marker can
achieve the required accuracy. The purpose of this study was to select a multiparameter panel, comprising urinary biomarkers and
clinical parameters, for BCa recurrence diagnosis. Experimental Design. Candidate biomarkers were measured in urine samples of
BCa patients with recurrence and BCa patients without recurrence. A multiplatform strategy was used for marker quantification
comprising a multiplexed microarray and an automated platform for ELISA analysis. A multivariate statistical analysis combined
the results from both platforms with the collected clinical data.Results.Thebest performing combination of biomarkers and clinical
parameters achieved an AUC value of 0.91, showing better performance than individual parameters. This panel comprises six
biomarkers (cadherin-1, IL-8, ErbB2, IL-6, EN2, and VEGF-A) and three clinical parameters (number of past recurrences, number
of BCG therapies, and stage at time of diagnosis). Conclusions. The multiparameter panel could be a useful noninvasive tool for
BCa surveillance and potentially impact the clinical management of this disease. Validation of results in an independent cohort is
warranted.
1. Introduction
Bladder cancer is the ninth most common cancer worldwide
and the seventh most common cancer in men with a world-
wide age-standardized rate of 9.0 per 100 000 men [1]. The
majority of newly diagnosed cases are nonmuscle invasive
disease (BCa) with 75% to 85% of patients presenting tumors
confined to the mucosa or submucosa (Ta, carcinoma in situ
(CIS), or T1 tumors) [2, 3]. Despite the good prognosis of
such tumors, there is a tendency for recurrence after initial
treatment.The probability of recurrencewithin 5 years ranges
from 30% to 80% and 10% to 30% of these cases will progress
to muscle invasive disease [3–5].
Follow-up is thus an essential aspect of BCa patient man-
agement and includes ongoing monitoring for recurrence
detection. Cystoscopy and urinary cytology are defined as the
gold standardmethods for both diagnosis and surveillance of
BCa [2]. Cystoscopy is highly sensitive but is still associated
with a significant false negative rate. Moreover, as a costly,
invasive, and uncomfortable procedure, it contributes to the
economic and psychological burden of BCa [6, 7]. Urinary
cytology has a higher specificity ranging from 85% to 100%
and a high sensitivity in high-grade tumors but it lacks
sensitivity in low-grade tumors [2, 8].
The management of patients with primary BCa diagnosis
and postsurgical surveillance could greatly benefit from
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Figure 1: Discovery study design.
new, noninvasive methods with improved sensitivity and
specificity. Urinary products of cancer growth or metabolism
are highly relevant, easy to obtain, and suitable for BCa
screening in these contexts. Urinary tests for diagnosis and
detecting recurrence have already been developed, including
FDA-approved BTA assays (BTA TRAK and BTA stat from
Polymedco) as well as the Alere NMP22 BladderChek
Test which are used for the diagnosis and monitoring of
BCa in conjunction with standard diagnostic procedures.
They yield improved sensitivity (up to 89%) compared to
urinary cytology which has a median sensitivity of only 35%.
However, benign urological conditions tend to influence the
specificity of these tests. They show a lower specificity than
urinary cytology: the median specificity of BTA TRAK, BTA
stat, and NMP22 is, respectively, 66%, 73%, and 73% whereas
urinary cytology has a median specificity of 94% [8–10]. A
recent review by van Rhijn et al. assessing the performance
of 18 markers showed that urinary markers generally have a
higher sensitivity but a lower specificity than urinary cytology
[8]. In the context of BCa surveillance, the review also
evaluated marker performance with regard to the detection
of recurrent bladder cancer and found a lower sensitivity for
most markers compared to their performance for primary
disease detection. Thus, single markers are not currently
suitable for incorporation into any clinical surveillance pro-
tocol to allow patients to undergo less frequent cystoscopic
evaluations.
The ideal urinary test should show good performance in
both sensitivity and specificity. As this is clearly not possible
with single markers, combining several markers in a multi-
plexed assay might provide a solution for optimizing a BCa
recurrence detection test.
A first (pilot) study was conducted by our group to
identify a biomarker candidate set with potential clinical
utility in BCa. The selection was made on the basis of a
molecular disease model for BCa. The candidate markers
were then evaluated in urine samples for their measurability
and detectability in urine as well as their selectivity for BCa.
This pilot study led to the definition of a five-biomarker panel
(IL-8, MMP-9, VEGF-A, PTGS2, and EN2) which showed a
better overall performance compared to individual markers
[11]. As this study compared a group of BCa patients to a
group of healthy donors, it only investigated the diagnostic
aspect of de novo BCa.
In this report, we describe a second (discovery) study
which aims at selecting a marker panel for BCa recurrence
diagnosis. Biomarkers selected in the pilot study as well as
other relevant candidate markers of the molecular disease
model were evaluated in urine samples of BCa patients with
recurrence and BCa patients without recurrence. Marker
measurement was performed on two different platforms:
a multiplexed microarray (BCa chip) and an automated
platform for 96-well plate ELISA analysis. Results from both
platforms were combined with clinical parameters for a
multivariate statistical analysis allowing the selection of a
panel of biomarkers and clinical parameters for the diagnosis
of BCa recurrence.
2. Materials and Methods
2.1. Study Design. The study design is described in Figure 1.
We had access to a biobank holding 80 samples from BCa
patients. In total, 19 markers were measured. Two analysis
platforms were used for the marker measurements and the
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results were included in a statistical analysis with the patients’
clinical parameters. Each study step is further described in
the sections below.
2.2. Specimen and Data Collection. The selection of patients
was based on the following inclusion criteria: the patient was
diagnosedwith BCa (cystoscopic and histological evidence of
BCa), the patient was treated for BCa prior to the sample col-
lection visit, and the patient has no history of muscle invasive
BCa. Recurrence-negative patients are defined as showing
no cystoscopic or histological evidence of BCa during mon-
itoring after treatment of de novo BCa. Recurrence-positive
patients are defined as showing cystoscopic and histological
evidence of BCa duringmonitoring after treatment of de novo
BCa.
First pass urines were collected from the selected bladder
cancer patients according to a standard operating procedure
and were spun at 150 g for 10 minutes. The supernatant was
aliquoted into 1mL samples and frozen and stored at −80∘C.
All individuals gave informed consent for sample donation
and the collection was approved by local ethical committee
(ref. 3/LO/0739).
The samples were collected during a monitoring visit.
For all samples, at least two monitoring visits are available:
one for the first diagnosis and one for the point in time
the sample was collected. Up to six additional visits between
first diagnosis and time of sample and up to four visits
after sample collection have been recorded. During the mon-
itoring visits, the following parameterswere collected: gender,
age, smoking status, date, grade, stage, recurrence, TURBT
(transurethral resection of the bladder tumor), and drug
treatment (name and start date).
Further clinical data was collected for the statistical
analysis and parameter performance regarding BCa recur-
rence diagnosis. Thus, the clinical parameter set used
includes the following parameters: gender, age at time of
diagnosis (age.diagnosis), age at time of sample collection
(age.sample), time between the first diagnosis and sam-
ple collection (months.diagnosis2sample), number of past
recurrences between the first diagnosis and time of sample
collection (no.past.recurrences), number of bacillus Calmette-
Guerin (BCG) therapies between the first diagnosis and time
of sample collection (BCG.therapy), number of mitomycin
therapies between the first diagnosis and time of sample
collection (mitomycin.therapy), and number of transurethral
resections of the bladder tumor between the first diagnosis
and time of sample collection (no.past.TURBTs).
According to availability of the full set of clinical phe-
notype parameters and availability of valid biomarker read-
outs, 45 samples from the initial biobank of 80 samples
could be included in the analysis, reflecting 27 patients
being recurrence negative and 18 patients being recurrence
positive.
2.3. Marker Quantification. Marker quantification was per-
formed on two separate platforms. The first platform, a
protein microarray (BCa chip), was used to measure the
urinary levels of 10 markers, decorin, VEGF-A, cadherin-
1, IL-6, ErbB2, EGFR, MMP-7, MMP-9, IL-8, and EN2,
while the second platform, an automated platform for 96-
well plate ELISA analysis, was used for the measurements
of the following 12 markers: PTGS2, FGFR-3, uroplakin-
3a, vimentin, MYC, tropomodulin-1, BIRC5, fibulin-3, p53,
MMP-9, IL-8, and EN2. Three markers (MMP-9, IL-8, and
EN2) were thus measured with both methods in order to
evaluate the concordance of the two analytical platforms.
2.3.1. BCa Chip
(1) Materials and Reagents. ARChip Epoxy (EP 02799374;
US 10/490543) was used as assay platform. Recombi-
nant human VEGF-A (293-VE-050), human VEGF-A anti-
body (MAB293) and human VEGF-A biotinylated anti-
body (BAF293), recombinant human MMP-7 (907-MP-
010), human MMP-7 antibody (clone 111439, MAB9072),
human MMP-7 biotinylated antibody (BAF907), recom-
binant human MMP-9 (CF, 911-MP-010), human MMP-
9 antibody (MAB936), human MMP-9 biotinylated anti-
body (BAF911), recombinant human EGFR (1095-ER-002),
human EGFR antibody (AF231), human EGFR biotiny-
lated antibody (BAF231), recombinant decorin (143-DE-100),
human decorin antibody (BAM1432) and human biotiny-
lated decorin antibody (clone 115413, BAM1431), recombinant
human ErbB2 (FC chimera, CF, 1129-ER-050), human ErbB2
antibody (clone 191924, MAB1129), human ErbB2 biotiny-
lated antibody (BAF1129), recombinant human cadherin-
1 (648-EC-100), human cadherin-1 antibody (clone 77308,
MAB18382), and human cadherin-1 biotinylated antibody
(BAF648) were derived from R&D Systems (Minneapolis,
MN). Recombinant human IL-6 (14-8069-80), human IL-6
antibody (14-7069-85), and human IL-6 biotinylated anti-
body (13-7068-85) were purchased from eBioscience (San
Diego, CA). The aptamer for EN2 (5󸀠-/5ThioMC6-D/AA
AAA AAA AAC GCA TAA TTA CCT CCA GAA GGA
GAG GTA ATT ATG CG-3󸀠, HPLC purified) [12] was
obtained from IDT IntegratedDNATechnologies (Coralville,
IA). Human EN2 (orb16876) was derived from Biorbyt
(Cambridge, UK). Human EN2 biotinylated antibody (bs-
11552R-biotin) was from BioSS (Woburn, MA). Recombinant
human IL-8 (574202), human IL-8 antibody (clone H8A5,
511501), and human IL-8 biotinylated antibody (clone E8N1,
511404) were purchased from Biolegend (San Diego, CA).
CRP/Dy647 (CON5, clone 7, D603080) was purchased from
Exbio (Vestec, Czech Republic). LowCross-Buffer (100 050)
from Candor (Wangen, Germany) was used as assay buffer.
Dy647 streptavidin was obtained from Dyomics (Jena, Ger-
many) and Tween 20 and sodium deoxycholate were derived
from Sigma-Aldrich (Vienna, Austria). Certified drug-free
urine (88121-CDF(F)) was used from UTAK Laboratories
(Valencia, CA).
(2) Chip Fabrication and Processing. Capture antibodies
were diluted in spotting buffer (1 × PBS (pH 7.2)/0.01%
sodium deoxycholate) to concentrations of 0.4mg/mL for
MMP-9, decorin, VEGF-A, IL-8, IL-6, MMP-7, cadherin-
1, ErbB2, and 0.16mg/mL for EGFR. The concentration of
spotted aptamer EN2 was 100𝜇M.The capture elements were
printed on proprietary ARChip Epoxy glass slides using the
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Arrayit Nanoprint contact spotter from GeneMachines (pin
SMP3). The spot-to-spot distance was 350 𝜇m. Each probe
was spotted in triplicate in 12 identical arrays at a relative
humidity of 50% and kept at 4∘C for a minimum of three
days. The arrayed slides were then blocked for 30min in
1 × PBS (pH 7.2)/0.1% Tween 20 and washed twice in 1 ×
PBS (pH 7.2). For one experiment, a 4-slide set was mounted
into an Arrayit Hybridization Cassette 4 × 16. The frames
create an incubation well for each array (7 × 7mm). We
used 12 arrays per slide, resulting in 48 arrays per slide
set. The sets accommodate 27 replicate measurements (three
arrays with three replicate spots and three repeats) of 10
calibration standards and 45 urine samples. Standard curves
for each marker were generated in synthetic urine diluted
with assay buffer (1 : 3). Each array was incubated with 50𝜇L
calibration standard or sample for 2.5 hours. After washing
three times with 1 × PBS (pH 7.2)/0.1% Tween 20, slides were
incubated for 45min with 50𝜇L biotinylated antibody mixes
(1 𝜇g/mL). Then, the slides were again washed and incubated
with 4 𝜇g/mL Dy647 streptavidin. At the end, the slides were
washed twice with 1 × PBS (pH 7.2)/0.1% Tween 20 and twice
in 1 × PBS (pH 7.2).
All incubation steps were carried out on the orbital shaker
at room temperature. The slides were stored in the dark until
scanning.
(3) Data Analysis. Processed slides were scanned using a
GenePix 4000B nonconfocal scanner (Molecular Devices,
Sunnyvale, CA) (𝜆ex: 635 nm, 𝜆em: 670 nm) and data were
analyzed with the GenePix 6.0 software. The photomultiplier
tube (PMT) voltage was held constant throughout the scans
for each analyte to allow data comparison. The mean signal
values were calculated from 27 background corrected data
points. Data that were out of the mean signal values ± the
standard deviation (SD) were excluded. Standard curves were
set up with GraphPad Prism 5 with a logistic fit.
2.3.2. Automated Platform for 96-Well Plate ELISA Anal-
ysis. Regarding the second platform, commercially available
ELISA kits were used to measure the markers’ urinary levels.
Supplemental Table 1 (see Supplementary Table 1 in Supple-
mentaryMaterial available online at http://dx.doi.org/10.1155/
2016/4591910) gives the kits sources and references. The
automated analysis was performed using an EVO100 robotic
platform (Tecan, Ma¨nnedorf, Switzerland). Each assay was
conducted according to the manufacturer’s instructions and
included a calibration curve in assay diluent as well as a
calibration curve in normal human urine (UTAK Labo-
ratories, Valencia, CA). Both were prepared using protein
standards provided in the ELISAkits. Four-parameter logistic
regression was used for curve fitting.
2.4. Data and Statistical Analysis
2.4.1. Sample Selection. Before the statistical analysis, further
sample selection was performed in order to use clinical
data most stringent with respect to recurrence events in
BCa. A complete history (no missing clinical parameters) is
thus required. Based on this additional criterion, 48 of the
initial 80 patients were included. Furthermore, three other
samples had to be excluded during the biomarker selection
process due to lack of valid biomarker readout (see section
below) leading to a final study cohort of 45 patients (27
nonrecurrence BCa patients and 18 recurrence BCa patients).
2.4.2. Biomarker Selection and Preprocessing. In total, 19
markers weremeasured in the study. To avoid artifacts caused
by missing value imputation, biomarkers were required to
have technically valid measurements for all samples in the
analysis. Biomarker candidates for the current analysis were
selected in such a manner that both the number of included
biomarker candidates and the number of included samples
are maximized. Under these constraints, a set of 13 biomarker
candidates with complete measurements for 45 out of the 48
samples was identified. Ten of the 13 markers were measured
with the first platform: decorin, VEGF-A, IL-8, cadherin-
1, IL-6, EN2, EGFR, ErbB2, MMP-7, and MMP-9. Three
were measured with the second platform: IL-8, MMP-9, and
fibulin-3.
Measurements below or above the valid range were set to
respective lower and upper detection limit values.
2.4.3. Individual Parameter Performance. Descriptive statis-
tics for the two patient groups for the individual clinical
parameters and individual biomarker candidates were per-
formed. In addition, their discriminative performance for the
two patient groups were evaluated using Z statistic.
2.4.4. Multivariate Statistical Analysis. As the aim of this
study was to determine a classifier for recurrence risk,
multimarker panels (composed of clinical parameters as
well as molecular readouts) were included in multivariable
regression models. Two strategies were employed for con-
structing these models: (i) manual selection based on indi-
vidual parameter association with the outcome parameter
and given clinical evidence and (ii) automatic selection using
Least Absolute Shrinkage and Selection Operator (LASSO)
regression for determining selection probability of individual
parameters.
For the selected parameter sets, a generalized linear
model (GLM) for predicting BCa recurrence was constructed
on the basis of given sample parameters. Receiver operator
characteristics (ROC) along with the correlation matrix for
model parameters were determined. Model performance in
terms of AUC was also determined. In addition to training
AUC values, leave-one-out cross-validation (LOOCV) AUC
values were determined.
3. Results
3.1. Biomarkers Measurements. Ten markers were analyzed
in 1 : 3 diluted patient’s urine using the BCa chip. The assay
sensitivity for each marker was visually determined and is
displayed in Table 1.
Highest assay sensitivity was observed for decorin (LOD
45 pg/mL). Best reproducibility was achieved for markers IL-
6 and EN2 (CV 7%). Limits of detection (LOD), linear ranges,
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Table 1: Biomarker measurements using the BCa chip.
Marker LOD (pg/mL) CV (%)
Decorin 45 11
VEGF-A 810 23
IL-8 405 9
Cadherin-1 2430 11
IL-6 135 7
EN2 729 7
ErbB2 450 18
EGFR 135 15
MMP-7 810 12
MMP-9 1350 14
LOD: limit of detection.
and CV of some BCamarkers were also described in previous
articles ([13] and submitted paper: [14]).
Twelve markers were measured in patient samples using
the automated platform for 96-well plate ELISA analysis.
The results are summarized in Table 2. No measurement
was obtained for uroplakin-3a as the full analysis could
not be carried out due to a technical difficulty. All other
assays except for fibulin-3 provided a calibration curve in
standardized urine. Fibulin-3 concentrations in samples were
thus determined using the calibration curve in assay diluent.
Three out of the 11 valid assays were not able to detect their
specific target in patient urine samples (vimentin, MYC,
and p53). Our previous study has shown similar results for
vimentin and p53. Moreover, although MYC was detected in
patient samples, the study’s ROC analysis rankedMYC as the
lowest performing marker [11].
As it was mentioned in Biomarker Selection and Prepro-
cessing, further statistical analysis was only performed on
three selected biomarkers: IL-8, MMP-9, and fibulin-3.
Two markers, namely, IL-8 and MMP-9, were measured
by both analytical systems. Significant positive correlations
were observed for both valid markers with Pearson 𝑅 values
of 0.83 for IL-8 and 0.70 for MMP-9.
3.2. Individual Parameters Performance
3.2.1. Clinical Parameters. In order to evaluate the potential
of individual clinical parameters for diagnosing BCa recur-
rence, these parameters were compared between the two
patient groups. Each parameter was also evaluated in terms
of discriminative performance for BCa recurrence (Table 3).
No apparent variance is detected in clinical parame-
ters allowing for the prediction of BCa recurrence. How-
ever, even though not significant individually, the param-
eters no.past.recurrences, BCG.therapy, and no.past.TURBTs
appear to exhibit some association with the target parameter.
These results clearly indicate the need of including additional
molecular biomarkers for improving diagnostic accuracy.
3.2.2. Biomarker Candidates. For each individual biomarker,
measurements were compared between the nonrecurrent
group and the recurrent group and their discriminative
performance is provided in Table 3.
From this analysis, no single biomarker candidate stands
out with the desired performance for a recurrence diagnostic
test. The highest AUC value, 0.7305, was found for ErbB2.
Some markers show AUC values lower than 0.5 (IL-6chip,
MMP-7chip, IL-8AP, andMMP-9AP). The other markers show
AUC values ranging from 0.5247 to 0.6872. This lack of
performance clearly emphasizes the need to use a profile of
parameters in order to achieve acceptable diagnostic perfor-
mance. The most promising markers in terms of individual
performance (VEGF-Achip, IL-8chip, EN2chip, and ErbB2chip)
were thus forwarded to multivariate analysis.
3.3. Combined Parameters Performance. As the individual
performances of the clinical parameters and the biomarker
candidates did not reach a sufficient level, various com-
binations of both types of parameters were evaluated to
define a multiparameter panel. Six multivariate regression
models were constructed (see Table 4). The corresponding
correlation matrix and the receiver operator characteristics
as well as the models’ AUC values are provided in Table 4.
Constructed models based on automatically selected
parameters show overall superior performance over the
models consisting of manually selected parameters. In case
of the clinical parameter models (Model 1 and Model 2),
the automatically determined model (Model 2) holds one
parameter less than the manually selected model but still
outperforms the manually constructed model. The drop in
the LOOCV AUC of Model 1 may be partially attributed to
highly correlated predictor variables no.past.recurrences and
no.past.TURBTs. Given the fact that Model 4 holds more
parameters than Model 3, the higher training AUC is not
surprising. However, Model 4 also exceeds Model 3 in terms
of the LOOCV AUC and appears therefore to be more suited
for diagnosing BCa recurrence. Similarly, Model 6 compris-
ing parameters from the automatically constructed clinical
parameters and biomarker candidates models supersedes its
counterpart Model 5. Again, as Model 6 holds one parameter
more, the increase in the training AUC (Model 5: 0.82; Model
6: 0.91) was to be expected. Nevertheless, we also observed an
increase in the LOOCV AUC (Model 5: 0.64; Model 6: 0.7).
Considering all the models presented here, Model 6 shows
the best performance in terms of AUC and reaches an AUC
of 0.70 in cross-validation.
4. Discussion
Due to the high rate of BCa recurrence, surveillance is a key
element of patient management. Thus, great clinical benefit
could be gained from improved tools for evidence-based
risk assessment, which would influence surveillance strategy.
The European Organization for Research and Treatment
of Cancer (EORTC) has developed a scoring system to
predict short- and long-term risks of disease recurrence and
progression after transurethral resection.This scoring system
is solely based on conventional clinical and pathological
predictors of outcomes (tumor stage and grade, number of
tumors, tumor size, concomitant CIS, and history of prior
disease recurrence) [15]. EORTC risk tables show significant
limitations and its risk classification could be improved by the
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Table 2: Biomarker measurements with the automated platform.
Marker Calibration curve in assay diluent Calibration curve in urine LOD (urine) Marker detection in samples
PTGS2 − + 5 ng/mL +
FGFR-3 + + 1000 pg/mL +
Uroplakin-3a − − N/A N/A
Vimentin + + 112.5 ng/mL −
MYC + + 1.25 ng/mL −
Tropomodulin-1 + + 2.5 ng/mL +
BIRC5 + + 1000 pg/mL +
Fibulin-3 + − 25 ng/mL (assay diluent) +
p53 + + 10 ng/mL −
MMP-9 + + 666.7 pg/mL +
IL-8 + + 125 pg/mL +
EN2 + + 1.25 ng/mL +
+: presence of calibration curve or marker detection in samples.
−: absence of calibration curve or no marker detection in samples.
N/A: not applicable; LOD: limit of detection.
Table 3: Discriminative performance of individual clinical parameters and biomarker candidates for BCa recurrence.
Clinical parameter Pr (>|𝑧|) AUC Biomarker candidate Pr (>|𝑧|) AUC
diagnosis2sample 0.42 0.50 Decorinchip 0.67 0.57
gender 0.89 0.51 VEGF-Achip
∗ 0.05 0.67
age.diagnosis 0.70 0.48 IL-8chip
∗ 0.08 0.69
age.sample 0.45 0.57 Cadherin-1chip 0.66 0.53
grade.diagnosis (G2/G3) 0.32/0.48 0.57 IL-6chip 0.65 0.48
stage.diagnosis 0.52 0.55 EN2chip
∗ 0.09 0.65
no.past.recurrences∗ 0.08 0.63 EGFRchip 0.86 0.53
BCG.therapy∗ 0.10 0.65 ErbB2chip
∗ 0.06 0.73
mitomycin.therapy 0.49 0.54 MMP-7chip 0.90 0.50
no.past.TURBTs 0.33 0.58 MMP-9chip 0.72 0.58
IL-8AP 0.74 0.47
MMP-9AP 0.46 0.50
Fibulin-3AP 0.54 0.52
∗Clinical parameters and biomarker candidates with the best individual AUC.
(a) grade.diagnosis: tumor grade at time of diagnosis; stage.diagnosis: tumor stage at time of diagnosis.The other clinical parameters are defined in the Specimen
and Data Collection.
(b) G2/G3: grade 2/grade 3.
(c) Biomarkers ending with chip were measured with the BCa chip and markers ending with AP were measured with the automated platform for 96-well plate
ELISA analysis.
updating and addition of new parameters [16–18]. According
to a comprehensive review of the literature by Kluth et al.
regarding the prognostic and prediction tools in BCa, clinical
utility and accuracy of such tools could be improved by
biomarkers [17].
Only a few studies have taken into consideration bio-
markers as parameters of prediction tools. One specific study
identified a panel of 5 cell cycle regulatory biomarkers (cyclin
E1, p53, p21, pRB, and p27) which improved the predictive
accuracy of BCa recurrence and survival after cystectomy
in patients with pTa-3N0M0 tumors [19]. In another study,
Rosser et al. evaluated the performance of a 10-biomarker
panel (IL-8, MMP-9, MMP-10, SERPINA1, VEGF-A, ANG,
CA9, APOE, SERPINE1, and SDC1) which achieved better
sensitivity (79%) than urine cytology (33%) for recurrent BCa
detection and outperformed any single biomarker [20].
In our discovery study, we evaluated the potential of
several biomarkers and clinical parameters for BCa recur-
rence diagnosis. Individual parameter performance analysis
showed that clinical data alone is not sufficient for the diag-
nosis of recurrence.Moreover, no single biomarker candidate
achieved an acceptable performance by itself. By combining
both types of parameters, clinical and molecular, we iden-
tified several multivariable regression models. The best per-
forming model (Model 6) achieved an AUC of 0.91, showing
better performance than the single parameters. It comprises
the following automatically selected (using LASSO) clinical
parameters and biomarker candidates: number of past recur-
rences, number of BCG therapies, stage at time of diagnosis,
cadherin-1, IL-8, ErbB2, IL-6, EN2, and VEGF-A.
Regarding clinical parameters, all of the manually
selected parameters are also included in Model 6 apart from
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Table 4: Multivariate regression models.
Model Strategy Description Included parameters AUC AUC(LOOCV)
Model 1 Manualselection
The model comprises clinical
parameters exhibiting on the
individual level some association
with the outcome parameter and
the clinically relevant age at time
of sample
no.past.recurrences,
BCG.therapy, no.past. TURBTs,
and age.sample
0.78 0.65
Model 2 Automaticselection
The model comprises clinical
parameters with a selection
probability greater than 50%
no.past.recurrences,
BCG.therapy, and stage.diagnosis 0.80 0.72
Model 3 Manualselection
The model comprises biomarker
candidates exhibiting on the
individual level some association
with the outcome parameter
VEGF-Achip, IL-8chip, EN2chip,
and ErbB2chip
0.72 0.51
Model 4 Automaticselection
The model comprises biomarker
candidates with a selection
probability greater than 50%
Cadherin-1chip, IL-8chip,
ErbB2chip, IL-6chip, EN2chip, and
VEGF-Achip
0.78 0.61
Model 5 Union of the parameters in Model 1 and Model 3 0.82 0.64
Model 6 Union of the parameters in Model 2 and Model 4 0.91 0.70
(a) Included parameters:
stage.diagnosis: stage of the tumor at time of diagnosis.
The other clinical parameters are defined in the Specimen and Data Collection.
(b) Markers ending with chip were measured with the BCa chip and markers ending with AP were measured with the automated platform for 96-well plate
ELISA analysis.
(c) LOOCV: leave-one-out cross-validation.
(d) Biomarker candidates chosen during manual selection for Model 3 are a subset of Model 4.
age at time of sample and number of TURBTs.The parameter
age at time of sample was included during manual selection
based on its presumed clinical relevance and was not based
on observed statistical association with the target parameter.
Number of TURBTs is highly correlated with number of past
recurrences and should therefore be omitted.
All the biomarkers identified as relevant in the indi-
vidual analysis are included in the selected model (IL-
8, ErbB2, EN2, and VEGF-A). The multivariate analysis
provided two additional markers: IL-6 and cadherin-1. All
six biomarkers were previously proved to be of interest with
regard to BCa recurrence. Indeed, a study suggested that
assessment of cytoplasmic cadherin-1 staining can predict
time to BCa recurrence [21] while Mahnken et al. found a
correlation between abnormal cadherin-1 immunostaining
and early tumor recurrence, identifying this parameter as
an independent predictor of recurrence-free survival [22].
A relationship between high expression levels of IL-8 in
malignant tissues and tumor recurrence was also found [23].
A similar finding was described for IL-6 [24]. Moreover,
a cytokine panel including both IL-8 and IL-6 showed
potential in tumor recurrence risk identification in patients
undergoing BCG treatment [25]. Several studies revealed the
correlation between VEGF-A and BCa recurrence, at the
mRNA level as well as the protein level [26–28]. As for ErbB2,
its overexpression has been associated with BCa and risks of
recurrence and progression but it is not yet clearly established
as a molecular marker in recurrent bladder tumors as some
studies showed varying results [29–32]. Finally, EN2 has been
studied as a potential urinary marker for BCa diagnosis
but was also shown to be secreted by recurrent nonmuscle
invasive BCa tumors [33].
Although links to recurrence or its mechanism are not
clearly established yet for all the selected biomarkers, they
all show a potential role for revealing BCa recurrence.
Combining these markers with clinical parameters appears
to be a good strategy for achieving acceptable performance
with regard to BCa recurrence diagnosis. Such a panel will
allow the determination of patient-specific profiles and could
greatly improve recurrence detection.
Although our findings show potential for the develop-
ment of new BCa surveillance tool, some limitations in our
study need to be considered. Indeed, the study includes only
a small number of samples due to stringent selection criteria.
Furthermore, the study design only allowed evaluating the
diagnosis of BCa recurrence, giving no information on the
prediction of BCa recurrence. Validation of our results in an
independent cohort shall be warranted.
5. Conclusions
In conclusion, cancer is a complex disease and as its detection
cannot rely on a single biomarker, the analysis of a profile of
biomarkerswill likely bemore accurate for such purpose [34].
The challenge remains thus in selecting those biomarkers
which reflect early tumor growth and disease activity. Our
multiplatform strategy allowed the screening of 19 urinary
markers for BCa recurrence diagnosis and led to a selection
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of six markers as well as three clinical parameters defining
a panel for patient segmentation. This multiparameter panel
outperformed any single biomarker or clinical parameter for
BCa recurrence diagnosis and could be a useful tool for BCa
surveillance scheme.
However, our discovery study shows limitations espe-
cially in terms of number of patients. The total number
of patient samples included in the statistical analysis was
reduced by our selection samplemethod.Moreover, our study
only evaluated the diagnostic aspect of recurrence in non-
muscle invasive BCa patients and did not take into consid-
eration the prediction aspect. According to the IBCN phases
classification for the development of diagnostic markers in
bladder cancer, our study corresponds to a phase II study,
evaluating clinical utility [35]. Further clinical validation of
the panel is thus needed, in a phase III study. A larger
independent validation study would allow the confirmation
of our findings and lead to the design of a novel patient
stratification concept as a risk estimating tool. Clinical man-
agement of BCa, especially surveillance, could greatly benefit
from stratification incorporating patient-specific biomarker
and clinical profiles.
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